Bio & Pharma
Theraject Asia applies for microneedle patent in US
The S.Korean company’s static pressure syringe technology utilizes its expertise in drug-injecting microneedles
By Oct 27, 2023 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
South Korea sets sights on fostering EDA tech to win HBM chip war
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![Theraject Asia applies for microneedle patent in US](https://www.kedglobal.com/data/ked/image/2023/10/27/ked202310270019.647x.0.jpg)
South Korean microneedle company Theraject Asia on Thursday said it recently applied for a US patent for a medical microneedle, specifically a constant pressure model that controls active drug penetration and resolves effect reproducibility.
As a system for delivering transdermal drugs using a microneedle hundreds of micrometers long, a microneedle can administer a variety of medicines depending on its size, strength and material. Though microneedles are growing in prominence as a cutting-edge technology, know-how in standardized transdermal injection is needed for drug reproducibility when applied to the skin.
Theraject Asia has secured technology for static pressure syringes that combines know-how in drug-injecting microneedles, enabling easy application to the skin under standardized physical conditions.
The company on Wednesday signed a joint research agreement with JW Pharmaceutical to use this technology for development of a hair loss treatment using microneedles.
“In 2019, we received from Theraject in the US an exclusive license for the original patent for a dissolvable pharmaceutical microneedle,” Theraject Asia CEO Kim Kyeong-dong said. “Since 2020, our focus has been finding methods to overcome obstacles to commercial application of a medical microneedle patch.”
Write to Ji-Hyun Lee at bluesky@hankyung.com
More to Read
-
-
Bio & PharmaGeneOne Life Science gets patent for coated microneedle tech in China
Apr 19, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaS.Korea's microneedle maker Raphas to enter US market
Mar 27, 2023 (Gmt+09:00)
1 Min read
Comment 0
LOG IN